The Role of the Androgen Receptor in Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

The Role of the Androgen Receptor in Triple-Negative Breast Cancer

Published:2013-07 Issue:4 Volume:9 Page:351-360
ISSN:1745-5065
Container-title:Women's Health
language:en
Short-container-title:Womens Health (Lond Engl)

Author:

Shah Payal D¹²,Gucalp Ayca¹²,Traina Tiffany A¹²

Affiliation:

1. Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA

2. Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA

Abstract

Greater than 70% of human breast cancers express the androgen receptor (AR). Emerging preclinical and clinical data suggest that AR may play a role in breast cancer pathogenesis and may serve as a therapeutic target in certain more difficult-to-treat breast cancer subtypes, such as triple-negative breast cancer. Although this is an area of active investigation, the clinical significance of this hormone receptor as a prognostic/predictive marker and its functional role in tumorigenesis is unclear. This review provides an update on the advances made in the last several years regarding the role of AR as a prognostic/predictive biomarker in breast cancer, the underlying biology of AR signaling in breast cancer development and the available clinical data for the use of androgen inhibition in the treatment of AR+ triple-negative breast cancer.

Publisher

SAGE Publications

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.2217/WHE.13.33

Reference65 articles.

1. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

2. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

3. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

4. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

5. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen Receptor Is Expressed in the Majority of Breast Cancer Brain Metastases and Is Subtype-Dependent;Cancers;2023-05-13

2. Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival;Advances in Therapy;2023-04-28

3. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer;Cancers;2022-12-30

4. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review;Pharmacological Reviews;2022-12-12

5. HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells;Molecular Biology Reports;2022-08-12